Form 4: ACHV COO Craig Donnelly Granted 50,000 Stock Options

Achieve Life Sciences' Chief Operations Officer, Craig Donnelly, was granted 50,000 stock options with an exercise price of $3.1, vesting over four years.

Summary

• Craig Donnelly, Chief Operations Officer of ACHIEVE LIFE SCIENCES, INC. (ACHV), was granted 50,000 stock options.
• The transaction date for this grant was October 1, 2025.
• Each stock option has an exercise price of $3.1.
• The options will vest as to 1/4 of the total award on the first anniversary of September 8, 2025 (i.e., September 8, 2026), and thereafter in substantially equal monthly installments over 36 months.
• The vesting is contingent upon Mr. Donnelly's continued service to the Issuer on each vesting date.
• The stock options have an expiration date of October 1, 2035.
• Following this transaction, Mr. Donnelly beneficially owns 50,000 derivative securities (stock options).

Sentiment

Score: 7

Explanation: The filing reports a standard executive compensation event (stock option grant), which is generally viewed positively as it aligns management incentives with shareholder interests. It does not contain any negative news or significant operational updates that would alter the company's fundamental outlook.

Positives

• The grant of stock options aligns the Chief Operations Officer's financial interests with those of the shareholders, incentivizing long-term performance.
• This is a standard component of executive compensation packages, indicating a commitment to retaining key management.

Future Outlook

The vesting schedule for the stock options, extending over four years, indicates an expectation of continued service from the Chief Operations Officer and a long-term incentive structure tied to the company's performance.

Industry Context

The grant of stock options to a Chief Operations Officer is a common practice in the biotechnology and pharmaceutical industry, used to attract, retain, and motivate key executives by linking their compensation to the company's stock performance and long-term value creation.

Comparison to Industry Standards

• The structure of this option grant, including a multi-year vesting schedule, is consistent with typical executive compensation practices observed in comparable life sciences companies.
• The exercise price being set at the market price on the grant date is standard for incentive stock options.

Stakeholder Impact

• Shareholders: Potential for future dilution if options are exercised, but also increased alignment of executive interests with shareholder value creation.
• Employees (specifically Craig Donnelly): Provides a significant long-term incentive and compensation component tied to company performance.

Next Steps

• The stock options will begin to vest on September 8, 2026, with subsequent monthly installments over 36 months, subject to continued service.

Key Dates

Recommendation

This Form 4 filing reports a routine executive stock option grant, which is a standard compensation practice and does not provide new fundamental information that would warrant a change in investment recommendation. While it aligns management incentives, it does not indicate a significant operational or financial event that would materially impact the company's valuation or outlook in the short term. Therefore, a 'hold' recommendation is appropriate, maintaining current positions based on existing fundamental analysis.

Keywords

ACHV, Achieve Life Sciences, Craig Donnelly, Stock Options, Form 4, Insider Transaction, Executive Compensation, COO